The Absolute Effect / Oncology Evidence / Evidence Index
FIGHT-207
In previously treated FGFR-altered advanced solid tumours, what antitumour activity does pemigatinib demonstrate across fusion/rearrangement and mutation cohorts?
Registry: NCT03822117 · Evidence reviewed 9 November 2026 · Aliases and follow-up publications consolidated.
Phase II open-label single-arm multicohort basket study.Primary-source evidence summaryStudy design, population and eligibility
Phase II open-label single-arm multicohort basket study.
Advanced solid tumours with FGFR1–FGFR3 fusions/rearrangements or activating mutations.
Treatment and comparator
Intervention: Pemigatinib 13.5 mg daily, 2 weeks on/1 week off.
Comparator: No randomized comparator; molecular cohorts.
Endpoints
ORR in cohorts A and B primary.
Key efficacy and clinical outcomes
ORR 26.5% in fusion/rearrangement cohort (13/49), 9.4% mutation cohort (3/32), 3.8% kinase-domain/uncertain cohort (1/26); median PFS 4.5 and 3.7 mo in A/B.
Source-reported outcome visualization
Values are reproduced from the cited report; bars are scaled within this figure. Previously treated FGFR-altered advanced solid tumour basket
Median survival and hazard ratios are not fixed-time event risks; NNT is not inferred from them.
Toxicity and treatment burden
Hyperphosphataemia 84%, stomatitis 53%; ocular/nail/skin toxicity.
Absolute effect and NNT/NNH
Single-arm basket; response is alteration- and tumour-context-dependent; no comparative effect.
NNT/NNH is not calculated unless a directly reported, comparable fixed-time risk difference supports it. Median survival and hazard ratios alone do not provide an NNT.
Critical interpretation and limitations
Single-arm basket; response is alteration- and tumour-context-dependent; no comparative effect.
This page is an evidence summary, not a substitute for multidisciplinary assessment or patient-specific decision-making.
Current-practice context
Review date: 9 November 2026. Primary publication and selected follow-up sources were reviewed. Full disease-specific guideline, regulatory-label and sequencing audit remains pending; verify current local recommendations and biomarker eligibility before clinical application.